



## FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

October 31, 2018

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051

Dear Sir/ Madam,

Sub:- Closure of US - FDA inspection at Company's manufacturing facility located at Waluj, Aurangabad.

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and disclosure Requirements) Regulations, 2015

This is further to the intimation given by the Company dated 20<sup>th</sup> August, 2018 with respect to US - FDA inspection of it's manufacturing facility located at B-8, MIDC Industrial Area, Waluj, Aurangabad, Maharashtra.

In response to the Form 483's issued by US FDA containing 8 Observations, the Company had submitted a detailed Compliance Report to the Regulator within the stipulated time.

It is hereby informed that, the Company has received an Establishment Inspection Report (EIR) for the said Manufacturing facility, which was inspected from 10<sup>th</sup> August, 2018 to 16<sup>th</sup> August, 2018 by US FDA. The facility is considered to be acceptable with regards to current Good Manufacturing Practices (GMPs) and the inspection stands closed.

Kindly take the above on record.

Thanking you,

Yours truly,  
For FDC LIMITED

Company Secretary

